Acute Myelogenous Leukemia (AML or ANLL)
Oncology·MeSH: Hodgkin Disease
Prevalence
30.0 / 100K
0 drugs in development·0 companies·1 clinical trial
Frequently asked questions
How many clinical trials target Acute Myelogenous Leukemia (AML or ANLL)?
There are 1 clinical trial targeting Acute Myelogenous Leukemia (AML or ANLL) tracked by BioSniper.
What is the prevalence of Acute Myelogenous Leukemia (AML or ANLL)?
The estimated prevalence of Acute Myelogenous Leukemia (AML or ANLL) is approximately 30.0 per 100,000 population.
Deep-dive into Acute Myelogenous Leukemia (AML or ANLL)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis